Insulet (PODD) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PODD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PODD, but not buy additional shares or sell existing shares.
View PODD analyst ratings or view top-rated stocks.

13 analysts have issued 1-year target prices for Insulet's shares. Their PODD share price forecasts range from $260.00 to $370.00. On average, they expect the company's share price to reach $330.00 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price.
View analysts price targets for PODD or view top-rated stocks among Wall Street analysts.

Insulet's stock was trading at $294.39 on January 1st, 2023. Since then, PODD shares have decreased by 3.5% and is now trading at $284.14.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PODD earnings forecast.

Insulet Co. (NASDAQ:PODD) announced its earnings results on Thursday, May, 4th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.14. The medical instruments supplier had revenue of $358.10 million for the quarter, compared to analyst estimates of $330.21 million. Insulet had a trailing twelve-month return on equity of 17.29% and a net margin of 0.04%. Insulet's revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.40 EPS.

ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Digital Health ETF (FDHT), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), Goldman Sachs Future Health Care Equity ETF (GDOC), Subversive Mental Health ETF (SANE), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI) and Nuveen ESG Mid-Cap Growth ETF (NUMG).

Insulet issued an update on its second quarter 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $380.24 million-$389.22 million, compared to the consensus revenue estimate of $362.68 million.

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (3.24%), Clearbridge Investments LLC (2.24%), Geode Capital Management LLC (2.13%), Bank of New York Mellon Corp (0.83%), Gateway Advisory LLC (0.79%) and William Blair Investment Management LLC (0.69%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $284.14.

Insulet (NASDAQ:PODD) has a market capitalization of $19.80 billion and generates $1.31 billion in revenue each year.

The company employs 2,600 workers across the globe.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for the company is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.